Corporate | 27 November 2015 08:00
HAEMATO AG: 43 % sales increase in Q3 2015 compared to the prior-year quarter
|
DGAP-News: HAEMATO AG / Key word(s): 9-month figures/Quarter Results
Corporate News of HAEMATO AG:
In the first 9 months of 2015 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS sales of EUR 161.99 million and profit of EUR 4.49 million. In the third quarter alone, sales amounted to EUR 60.52 million (prior-year quarter: EUR 42.24 million). “In Q3 2015 the HAEMATO Group has exceeded sales of the prior-year quarter by 43 %. The doubling of production capacity has paid off. We are confident about the further development in Q4 of 2015 and the year 2016”, says Dr Christian Pahl, Member of the Management Board of HAEMATO AG. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. Botulinum preparations and hyaluronic acid are strong growing product lines. HAEMATO AG is listed in the Entry Standard (Open Market) on the Frankfurt Stock Exchange.
Key figures for the share of HAEMATO AG:
Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de
2015-11-27 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
|